NOVOZYMES NORTH AMERICA, INC.

Lobbying for NOVOZYMES NORTH AMERICA, INC.

Filing · LD-2 quarterly report Q3 report

Reporting period

3rd Quarter 2026

July 1 - Sep 30 · Posted Oct 20, 2026

Expenses

$110,000

What this organization spent lobbying with its own staff. Reported using the LDA's own definitions (method A): the three LDA methods count different costs, so an expenses figure is not comparable across filers that used different ones.

Client based in

North Carolina

Official filing document

Government bodies contacted 3

The chambers, agencies and offices the filer named. It does not say who inside them was contacted, or when. Each name opens every filing that named the same body.

Lobbying activity 3

Environment/Superfund

Issues related to renewable fuels and expanded availability of E15, including education and advocacy concerning the biofuels industry.

Agriculture

Issues pertaining to nutrition and Generally Recognized as Safe (GRAS) requirements, including FDA regulation of food and feed ingredients, GRAS modernization, national uniformity; issues pertaining to biotechnology, including H.R. 2756, the National Biotechnology Initiative Act of 2025; and issues related to dietary supplements, including H.R. 7366, the Dietary Supplement Regulatory Uniformity Act.

Transportation

Issues pertaining to supply chain operations, movement of containers, SHIP IT Act (not yet introduced) related issues, and tariffs.

Bills named in this filing 2

H.R. 2756
National Biotechnology Initiative Act of 2025
H.R. 7366
Dietary Supplement Regulatory Uniformity Act

Source: federal Lobbying Disclosure Act filing, reproduced as filed. Bills are parsed from the activity descriptions.